Zi-Xuan Wang

Zi-Xuan Wang

Auto-generated profile, based on publicly available information

Zi-Xuan Wang

The Departments of Pathology, Anatomy, & Cell Biology (Pettengill, Peiper, Wang) and Surgery (Wang), Thomas Jefferson University, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 1998 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ZWZi-Xuan Wang
Zi-Xuan Wang
JBJoanne F. Berson
Joanne F. Berson
TZTianyuan Zhang
Tianyuan Zhang
YCYin-Hua Cen
Yin-Hua Cen
YSYi Sun
Yi Sun
SPStephen C. Peiper
Stephen C. Peiper
The interaction of human immunodeficiency virus type 1 (HIV-1) with CD4 and one of a cadre of chemokine receptors triggers conformational changes in the HIV-1 envelope (Env) glycoprotein that lead to membrane fusion. The coreceptor activity of the second extracellular loop of CXCR4, which is restricted to dual tropic and T-tropic strains, was insensitive to the removal of charged residues either singly or in combinations by alanine scanning mutagenesis or to the conversion of acidic residues to lysine. Conversion of Asp-187 to a neutral residue exclusively unmasked activity with M-tropic Env in fusion and infection experiments. Insertion of the D187V mutation into chimeras containing extracellular loop 2 of CXCR4 in a CXCR2 framework also resulted in the acquisition of M-tropic coreceptor activity. The independence of CXCR4 coreceptor activity from charged residues and the extension of its repertoire by removing Asp-187 suggest that this interaction is not electrostatic and that coreceptors have the potential to be utilized by a spectrum of Env, which may be masked by charged amino acids in extracellular domains. These findings indicate that the primary structural determinants of coreceptors that program reactivity with M-, dual, and T-tropic Env are surprisingly subtle and that relatively insignificant changes in CXCR4 can dramatically alter utilization by Env of varying tropism.

10 July 2020 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Closed access
RJRun Jin
Run Jin
MPMatthew A. Pettengill
Matthew A. Pettengill
NHNicole L. Hartnett
Nicole L. Hartnett
HAHerbert E. Auerbach
Herbert E. Auerbach
SPStephen C. Peiper
Stephen C. Peiper
ZWZixuan Wang
Zixuan Wang
Context.—: We implemented multiple nucleic acid amplification test platforms because of the limited availability of test kits for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the early stages of the pandemic. Interpretation of results generated by different platforms and prioritization for testing algorithms required cross-comparison. Objective.—: To compare the analytical sensitivity of 3 commercial SARS-CoV-2 molecular assays, selected samples were studied in parallel with Cobas SARS-CoV-2 test, NxTAG CoV Extended Panel, and ID NOW COVID-19 assays. Design.—: A total of 8043 SARS-CoV-2 tests performed from March 22 to April 19, 2020, were included in this study. For all 1794 positive specimens detected by the cobas SARS-CoV-2 assay, the cycle threshold (Ct) values were manually tracked and plotted to demonstrate the distribution of sample viral levels. Additionally, 50 and 63 low-positive specimens (Ct values >32) as well as 50 and 61 consecutive positive specimens by the cobas assay were tested with NxTAG and ID NOW, respectively, to estimate their relative sensitivities. Results.—: The Ct values of cobas SARS-CoV-2–positive samples were evenly distributed throughout ranges of 13.32 to 39.50 (mean, 25.06) and 13.60 to 42.49 (mean, 26.45) for ORF1 and E gene targets, respectively. NxTAG reliably detected only specimens with E gene Ct values lower than 33, and is estimated to detect 89.4% of positive specimens detected by cobas assay. ID NOW had performance variation independent of Ct value and is estimated to detect 83.5% of cobas positives. Conclusions.—: Clinical specimens exhibit a wide range of viral burden, with a significant portion at low levels. Analytical sensitivity of testing platforms is critical for reliable detection of SARS-CoV-2 and uniform care to patients.

22 February 2015 in Molecular Cytogenetics
Verified
Journal Article
Open access
PDF file
WDWhitney A Dobek
Whitney A Dobek
HKHyung-Goo Kim
Hyung-Goo Kim
CWCedric A Walls
Cedric A Walls
LCLynn P Chorich
Lynn P Chorich
STSandra Pt Tho
Sandra Pt Tho
LLLawrence C Layman
Lawrence C Layman
Females with Xp;Yq translocations manifest short stature and normal fertility, but rarely have follow-up. The study purpose was to define the phenotype of a family with t(X;Y)(p22.3;q11.2), determine long-term reproductive function, and compare to all reported female cases. Comprehensive clinical and molecular analyses were performed on the female proband, who had regular menses, normal endocrine function, and three pregnancies spanning seven years--a normal liveborn male and two with unbalanced translocations (liveborn female and stillborn male). The translocation truncated KAL1 and deleted 44 genes on der(X). Our report constitutes the longest follow-up of an X;Y translocation female. She had no evidence of Kallmann syndrome, gonadoblastoma, or cardiovascular disease. Detailed analysis of 50 published female cases indicated a uniform lack of follow-up and significant morbidity—intellectual disability (10%), facial dysmorphism (28%), eye abnormalities (14%), and skeletal defects (28%). Our findings indicate normal ovarian function to date in a woman with an t(X;Y)(p22.3;q11.2). However, additional published studies in the literature suggest careful follow-up is necessary and contradict the generalization that females with Xp;Yq translocations are usually normal except for short stature.

5 October 2013 in Cancer Biology & Therapy
Verified
Journal Article
Open access
PDF file
NZNicholas G Zaorsky
Nicholas G Zaorsky
YSYunguang Sun
Yunguang Sun
ZWZixuan Wang
Zixuan Wang
Joshua PalmerJoshua Palmer
Joshua Palmer
PFPaolo Fortina
Paolo Fortina
BLBo Lu
Bo Lu
RTOG 0839 is a Phase II study of pre-operative chemoradiotherapy with or without panitumumab in potentially operable locally advanced non-small cell lung cancer (NSCLC). The investigational agent, panitumumab, is an anti-epithelial growth factor receptor (EGFR) antibody that improves progression-free survival in chemorefractory metastatic colorectal cancer (mCRC). Recently, both KRAS mutational status (i.e., mutated or not) and subtype (i.e., activating or inactivating) have been shown to be predictive of response to anti-EGFR therapy in mCRC. However, in NSCLC, it is unknown if KRAS mutational status or subtype predict benefit to anti-EGFR therapies because of unique genetic and epigenetic factors unique to each cancer. We present a patient with stage III NSCLC containing a KRAS G12D activating mutation who had a partial pathologic response, with disappearance of a minor KRAS mutant clone. This case suggests possible eradication of the G12D KRAS lung cancer clones by concurrent chemoradiation with panitumumab.

14 August 2015
Verified
Book Chapter
Closed access
PDF file
JCJoanna S.Y. Chan
Joanna S.Y. Chan
RDRossitza Draganova-Tacheva
Rossitza Draganova-Tacheva
WJWei Jiang
Wei Jiang
ZWZi-Xuan Wang
Zi-Xuan Wang
SPStephen Peiper
Stephen Peiper

1 May 2016 in Clinical OMICs
Verified
Journal Article
Closed access
SPStephen C. Peiper
Stephen C. Peiper
EJErica Johnson
Erica Johnson
ZWZi-Xuan Wang
Zi-Xuan Wang